ENLV Company Profile and Key Details

ENLV has shown mixed momentum, gaining 2.87% over the past week and -7.55% over the past quarter, though year-to-date performance is up 39.36%. Short-term trend indicators are mixed aligned (SMA20 4.69%, SMA50 18.13%, SMA200 7.41%). The stock’s 14-day RSI is 57.6 (neutral), while the ATR of 0.09 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -45.24% below its high and over 74.24% above its low. Average 10-day trading volume of 339.16 thousand shares is significantly above the 3-month average of 220.39 thousand, indicating heightened recent market interest.

Enlivex Therapeutics Ltd. has 17.49 million shares outstanding. The public float is 4.82 million shares, elevated short interest at 1.06% of float. This equals 177.54 thousand shares. The short ratio is 0.61 days. Institutional investors hold 7.75% of the float. Insiders own 81.4%.

Enlivex Therapeutics Ltd. generated EPS of -$0.53 over the past year. Five-year average earnings growth is 7.57%. Wall Street analysts project EPS growth of -6.39% annually over the next five years. The latest quarter delivered EPS of -$0.31. The next quarter is forecast at -$0.09. Next year's EPS is expected at $36.76. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 6 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $80.00 to $13.00. The high target offers 7172.73% upside. The low target suggests 1081.82% downside. The mean target is $25.33. This offers 2202.73% upside. Enlivex Therapeutics Ltd. earnings surprise history is a mixed track record. The quarter that ended September 04, 2026, missed forecasts by 0.0%. The prior quarter beat by 666.67%. Over the last six quarters, Apple has recorded several small beats. These include -50.0% in August 29, 2025.

Enlivex Therapeutics Ltd. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.42. This means the shares are trading above this model’s fair value.

Enlivex Therapeutics Ltd. (NASDAQ:ENLV) closed at $1.10 USD, losing -$0.06 (-5.17%) from the previous close of $1.16. The stock is currently mid-range between its 52-week high and low $1.02 and $27.15. With a market capitalization of about $18.52 million, Enlivex Therapeutics Ltd. is classified as a micro-cap and shows higher-than-market volatility (beta ~1.42). Key stats such as the average daily volume over the past year has been around 226.57 thousand shares, in line with its 52-week average. Headquartered in Ness Ziona, TA, Enlivex Therapeutics Ltd. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Oren Hershkovitz, the company employs approximately 34 people and listed since July 31, 2014. Enlivex Therapeutics Ltd., established in 2005 and based in Nes Ziona, Israel, operates as a clinical-stage biotechnology firm dedicated to macrophage reprogramming immunotherapy.

Enlivex Therapeutics Ltd. trades at a P/E ratio of 0.0, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 The P/FCF stands at -1.68, also below market averages.

Our AI price prediction model suggests that Enlivex Therapeutics Ltd. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -85.45%, with price expected at $0.16 by September 18, 2026, within a range of $0.00 to $0.92 3-Month Outlook: Projected fall of -97.27%, reaching $0.03 by December 03, 2026, with a range of $0.00 to $0.48. 1-Year Outlook: Projected loss of -70.91%, with price at $0.32 by September 03, 2027, within a range of $0.00 to $0.61.

Enlivex Therapeutics Ltd. (NASDAQ:ENLV) shares are up 39.36% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Enlivex Therapeutics Ltd. trading at a premium to the broader market with a P/E of 0.0. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $15.96, suggesting 1350.91% upside. Our AI forecast model points to short-term weakness (-85.45% over two weeks), a medium-term fall (-97.27% over three months), and a longer-term loss (-70.91% over one year), with expected trading ranges indicating moderate volatility.